Global Calcium Secures FDA Warning Letter Closure After Corrective Action Review

A Warning Letter closure does not mark the end of FDA scrutiny, and the notice issued to Global Calcium Pvt. Limited makes that explicit. The Bangalore-based API and drug manufacturer received closure of Warning Letter 320-25-30, originally dated January 16, 2025, after the agency completed its evaluation of the firm's corrective actions. For QA directors managing post-warning letter remediation programs, the language of the closure is as instructive as the closure itself.

FDA's compliance officer stated that the agency's evaluation indicates Global Calcium "appears to have addressed" the cited deviations, a conditional framing that stops well short of verified resolution. The closure letter explicitly reserves the right to pursue future regulatory action if deviations are observed during subsequent inspections or through other means. Under 21 CFR Part 211, sustained compliance is an ongoing obligation, not a milestone that a closure letter satisfies.

The phrase "adequacy and sustainability" in the FDA's notice carries operational weight. Adequacy refers to whether the CAPA responses directly resolved the cited observations; sustainability requires that the corrective systems hold across inspection cycles, personnel changes, and production scale. Firms that treat a Warning Letter closure as a remediation endpoint rather than a compliance checkpoint have historically faced reinspection findings that reopen regulatory exposure.

Global Calcium operates under FEI 3004094136 and falls under the oversight of the Center for Drug Evaluation and Research (CDER), Division of Drug Quality I. Indian API manufacturers supplying regulated markets remain a consistent focus of CDER's foreign inspection program, and closure of a Warning Letter does not remove a facility from the inspection queue or alter its risk-based scheduling.

For plant heads and regulatory affairs leads at similarly situated facilities, the Global Calcium closure is a useful reference point: documentation of corrective actions must be structured to demonstrate not only that deviations were addressed, but that the underlying quality systems, aligned with ICH Q10 principles, are capable of preventing recurrence under routine operating conditions.

The next scheduled inspection of Global Calcium's Koramangala facility will serve as the first formal test of whether the corrections documented in response to Warning Letter 320-25-30 have translated into durable process controls.

Source: FDA CDER via What's New: Drugs RSS Feed, August 6, 2026.